CME Group (CME) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
24 Apr, 2026Executive summary
Achieved record Q1 2026 with revenue of $1.9 billion, up 14% year-over-year, and highest-ever average daily volume of 36.2 million contracts, up 22% year-over-year, with records across all six asset classes and major regions.
Net income rose 20% to $1.2 billion, with diluted EPS at $3.18 and adjusted EPS at $3.36; adjusted net income margin was 64.9%.
Operating margin improved to 72.8%, reflecting strong revenue growth and controlled expenses.
Delivered record capital efficiency, saving clients over $85 billion in margin per day, and ended the quarter with open interest up 11% year-over-year.
Continued innovation with regulatory approval for expanded cross-margining, upcoming 24/7 crypto trading, and migration of agricultural products to the cloud.
Financial highlights
Clearing and transaction fee revenue grew 15% year-over-year to $1.5 billion, driven by volume growth and pricing structure.
Market data revenue reached a record $224 million, up 15% year-over-year, marking 32 consecutive quarters of growth.
Total revenue was $1.9 billion, up 14% from Q1 2025; adjusted operating income was $1.4 billion with a 72.8% margin, both record highs.
Adjusted net income was $1.2 billion and adjusted diluted EPS was $3.36, both up 20% year-over-year.
Returned $3.2 billion to shareholders via $2.7 billion in dividends and $536 million in share repurchases.
Outlook and guidance
Confident in continued value delivery to clients and shareholders, supported by ongoing investments in technology and product innovation.
Expense guidance for 2026 remains at $1.695 billion, with expected growth in occupancy and technology costs as cloud migration progresses.
Management expects continued market volatility due to geopolitical tensions and macroeconomic uncertainty, supporting elevated trading volumes.
Latest events from CME Group
- Board candidates stress governance, risk oversight, and shareholder advocacy for the 2026 meeting.CME
Proxy filing16 Apr 2026 - Shareholders will vote on director elections, auditor ratification, and key governance amendments.CME
Proxy filing23 Mar 2026 - Shareholders to vote on major governance reforms, executive pay, and director elections.CME
Proxy filing23 Mar 2026 - Proposal to eliminate Class B director election rights, with payments to affected shareholders.CME
Proxy Filing12 Mar 2026 - Shareholders to vote on eliminating Class B director election rights amid record financial performance.CME
Proxy Filing12 Mar 2026 - Global growth, product innovation, and high margins drive record performance and shareholder returns.CME
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Record 2025 growth fueled by innovation, global reach, and strong capital efficiencies.CME
Investor presentation3 Mar 2026 - Record revenue, earnings, and trading volumes in 2025, with strong capital returns.CME
Q4 20254 Feb 2026 - Record financials, all proposals approved, and strong outlook amid competition and litigation.CME
AGM 20253 Feb 2026